Refine
Has Fulltext
- yes (21)
Is part of the Bibliography
- yes (21)
Year of publication
Document Type
- Journal article (21)
Language
- English (21)
Keywords
- Merkel cell carcinoma (8)
- polyomavirus (4)
- cell staining (3)
- melanoma (3)
- Merkel cell polyomavirus (2)
- PD-L1 (2)
- apoptosis (2)
- large T antigen (2)
- melanomas (2)
- polymavirus (2)
- B-cell lymphoma (1)
- B-cells (1)
- BRAF (1)
- CD274 (1)
- CD30 (1)
- CD8(+) (1)
- Cutaneous lymphoma (1)
- EGR1 (1)
- Epigenetic regulation (1)
- GSK3 (1)
- HDAC (1)
- Hautkrebs (1)
- Histone deacetylase (1)
- JAK2 (1)
- Krebs <Medizin> (1)
- LSD1 (1)
- Large T antigen (1)
- Lysine-specific methylase (1)
- MCC (1)
- MCPyV (1)
- MCV-negative (1)
- Medizin (1)
- Melanoma (1)
- PIK3CA mutations (1)
- RNA modification (1)
- T antigen (1)
- T-antigen (1)
- T-antigens (1)
- TP53 (1)
- Tubulin (1)
- YTHDF1 (1)
- akt (1)
- antibody–drug conjugates (1)
- antitumor immunity (1)
- artesunate (1)
- breast cancer (1)
- cancer (1)
- cancer treatment (1)
- case report (1)
- cell cycle (1)
- cell membranes (1)
- chromatin regulator (1)
- copy number variations (1)
- coronavirus disease 2019 (1)
- cultured fibroplasts (1)
- cutaneous T-cell lymphoma and Merkel cell carcinoma (1)
- cutaneous T-cell-lymphoma (1)
- epigenetic reader (1)
- epitranscriptome (1)
- expression (1)
- ferroptosis (1)
- glycogen synthase kinase 3 (1)
- heat shock response (1)
- histology (1)
- histone (1)
- histone methyltransferase PRDM8 (1)
- immune cell infiltration (1)
- immunohistochemistry techniques (1)
- large cell transformation (1)
- lung cancer (1)
- lymphocytes (1)
- m\(^6\)A (1)
- melanin (1)
- melanocytes (1)
- melanoma cell (1)
- melanoma cells (1)
- membrane proteins (1)
- membrans proteins (1)
- miRNA (1)
- microvessel density (1)
- migraine (1)
- mycosis fungoides (1)
- oncodermatology (1)
- p53 (1)
- panel sequencing (1)
- phthalazinone pyrazole (1)
- polymerase chain reaction (1)
- rare (1)
- reporter genes (1)
- responses (1)
- retinoblastoma protein (1)
- senescence (1)
- severe acute respiratory syndrome coronavirus 2 (1)
- skin squamous cell carcinoma (1)
- squamous cell (1)
- subtypes (1)
- survival (1)
- tertiary lymphoid structures (1)
- triptan (1)
- tumor (1)
- tumor suppressor genes (1)
- tumors (1)
- vascular endothelial growth (1)
- vesicles (1)
- viral carcinogenesis (1)
Institute
Elucidating the mechanism of action of domatinostat (4SC-202) in cutaneous T cell lymphoma cells
(2019)
Background
Targeting epigenetic modifiers is effective in cutaneous T cell lymphoma (CTCL). However, there is a need for further improvement of this therapeutic approach. Here, we compared the mode of action of romidepsin (FK228), an established class I histone deacetylase inhibitor, and domatinostat (4SC-202), a novel inhibitor of class I HDACs, which has been reported to also target the lysine-specific histone demethylase 1A (LSD1).
Methods
We performed MTS assays and flow cytometric analyses of propidium iodide or annexin V-stained cells to assess drug impact on cellular proliferation, cell cycle distribution, and survival. Histone acetylation and methylation as well as caspase activation was analyzed by immunoblot. Gene expression analysis was performed using NanosString technology. Knockdown and knockout of LSD1 was achieved with shRNA and CRISPR/Cas9, respectively, while the CRISPR/Cas9 synergistic activation mediator system was used to induce expression of endogenous HDACs and LSD1. Furthermore, time-lapse fluorescence microscopy and an in vitro tubulin polymerization assay were applied.
Results
While FK228 as well as 4SC-202 potently induced cell death in six different CTCL cell lines, only in the case of 4SC-202 death was preceded by an accumulation of cells in the G2/M phase of the cell cycle. Surprisingly, apoptosis and accumulation of cells with double DNA content occurred already at 4SC-202 concentrations hardly affecting histone acetylation and methylation, and provoking significantly less changes in gene expression compared to biologically equivalent doses of FK228. Indeed, we provide evidence that the 4SC-202-induced G2/M arrest in CTCL cells is independent of de novo transcription. Furthermore, neither enforced expression of HDAC1 nor knockdown or knockout of LSD1 affected the 4SC-202-induced effects. Since time-lapse microscopy revealed that 4SC-202 could affect mitotic spindle formation, we performed an in vitro tubulin polymerization assay revealing that 4SC-202 can directly inhibit microtubule formation.
Conclusions
We demonstrate that 4SC-202, a drug currently tested in clinical trials, effectively inhibits growth of CTCL cells. The anti-cancer cell activity of 4SC-202 is however not limited to LSD1-inhibition, modulation of histone modifications, and consecutive alteration of gene expression. Indeed, the compound is also a potent microtubule-destabilizing agent.